Evidence map›Paper›PMID 38473872›Full record

ArticleInternational journal of molecular sciences2024

Mechanism of Action of Antitumor Au(I) N-Heterocyclic Carbene Complexes: A Computational Insight on the Targeting of TrxR Selenocysteine.

Iogann Tolbatov, Paolo Umari, Alessandro Marrone

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Iogann TolbatovDepartment of Physics and Astronomy, University of Padova, Via F. Marzolo 8, 35131 Padova, Italy.ORCID 0000-0001-9700-5331
Paolo UmariDepartment of Physics and Astronomy, University of Padova, Via F. Marzolo 8, 35131 Padova, Italy.
Alessandro MarroneDipartimento di Farmacia, Università "G d'Annunzio" di Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.ORCID 0000-0002-8311-8172

Funding

THE EUROPEAN UNION - NEXT-GENERATION EU "PNRR M4C2-Investimento 1.4- CN00000041"
6 · The paper itself

Abstract

The targeting of human thioredoxin reductase is widely recognized to be crucially involved in the anticancer properties of several metallodrugs, including Au(I) complexes. In this study, the mechanism of reaction between a set of five N-heterocyclic carbene Au(I) complexes and models of the active Sec residue in human thioredoxin reductase was investigated by means of density functional theory approaches. The study was specifically addressed to the kinetics and thermodynamics of the tiled process by aiming at elucidating and explaining the differential inhibitory potency in this set of analogous Au(I) bis-carbene complexes. While the calculated free energy profile showed a substantially similar reactivity, we found that the binding of these Au(I) bis-carbene at the active CysSec dyad in the TrxR enzyme could be subjected to steric and orientational restraints, underlining both the approach of the bis-carbene scaffold and the attack of the selenol group at the metal center. A new and detailed mechanistic insight to the anticancer activity of these Au(I) organometallic complexes was thus provided by consolidating the TrxR targeting paradigm.

Indexed as

Antineoplastic AgentsCoordination ComplexesGoldHumansMethaneSelenocysteineThioredoxin-Disulfide ReductaseAntineoplastic AgentscarbeneCoordination ComplexesGoldMethaneSelenocysteineThioredoxin-Disulfide Reductaseanticancer metallodrugsDFT calculationsgold(I) complexesN-heterocyclic carbenesproteinsthioredoxin reductase TrxR

Identifiers

PMID38473872
PMCPMC10932012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.